INTRODUCTION
Epilepsies comprise a clinically complex group of neurological disorders defined by recurrent spontaneous seizures [1] , with an age-adjusted global prevalence estimated in the range of 2.7-17.6 per 1,000 individuals [2] . The most common types of epilepsies represent the heterogeneous group of acquired and non-acquired Adult Focal Epilepsies (AFE), idiopathic Genetic Generalized Epilepsies (GGE), and idiopathic childhood focal Rolandic Epilepsies (RE). The genetic architecture of these common epilepsies is presumed to be complex as it has been described by a wide range of syndrome specific variant associations, as well as a few shared seizure susceptibility variants (for review see [3] ). Twin studies have shown strong but differential concordance rates among epilepsies, including GGE and AFE with ~80% and ~40%, respectively [4 5] , while the genetic contribution to RE may be related to the underlying electroencephalogram (EEG) pattern rather than the seizures themselves [6] . Despite these differences, familial enrichment for seizure disorders has been demonstrated and genetic risk factors in a single gene (GRIN2A) have recently been identified in > 7.5% of RE patients [7] .
Copy number variants (CNVs) are genomic segments between 50 bp and 3 Mb in size which can behave as a loss and/or gain of genomic sequence relative to the reference genome based on the number of copies present [8] . CNVs are a significant source of genetic variation between two individuals and can, depending on their location on the chromosomes, cause changes in gene dosage, alternative splicing, or even lead to gene fusion events [9] . Microdeletions, defined as large (i.e. >400 kb) and rare CNVs (MAF < 1%) with a deletion behavior, are more likely to have damaging effects than duplications [8 10 ]. In addition, duplications are more prone to false positive calls as they are more difficult to identify in genotype array data.
Microdeletions are associated with a broad spectrum of neurological diseases such as autism (ASD) [11] , schizophrenia (SCZ) [12] and intellectual disability (ID) [13] . In this regard, twelve genomic regions prone to exhibit copy number rearrangements or CNV "hotspot loci" have been reported to increase the risk for neurodevelopmental disorders [14] , seven of them directly associated to epilepsy including 1q21.1, 15q11.2, 15q13.3, 16p11.2, 16p12, 16p13.11, and 22q11.2 to GGE [15] [16] [17] [18] , and also 16p11.2 to RE and AFE [19 20] . The relationship to epilepsy of the remaining 5 loci, namely 3q29, 10q22q23, 15q24, 17q12, and 17q21.3 remains to be elucidated. Overall, how these large and polygenic microdeletions increase risk for neurodevelopmental disorders is not fully understood. However, recent evidence from deletions in patients with GGE show an enrichment in genes involved in neurodevelopmental processes [18] . Whether this enrichment is also found in other types of common epilepsies has not yet been evaluated. Previous results support nonrecurrent deletions in RBFOX1 [20] [21] [22] , NRXN1 [23] , and GRIN2A [7 24] in candidate gene studies in GGE/RE/AFE, GGE, and RE, respectively. However, a genome-wide comparison for shared or subtype specific deleted genes in GGE, RE, and AFE has not been conducted.
Due to the low frequency of deletions, large sample sizes are required to identify novel susceptibility genes and to decipher syndrome-specific patterns. Considering that previous microdeletion associations are generally reported only within a particular type of epilepsy, our goal was to evaluate the global and specific contribution of microdeletions across GGE, RE, and AFE. Thus to investigate the deletion burden landscape for common types of epilepsy, here we present the largest combined microdeletion study to date for these traits, examining a total of 9,200 individuals (2,454 epilepsy cases and 6,746 controls). We combined the microdeletions found in a published GGE cohort with unpublished genome-wide microdeletions found in RE [19] and AFE [20] studies. We investigated the combined and sub-type specific burden of microdeletions, as well as their frequency, distribution and gene content. Finally, we assessed the protein-protein interactions and tissue specific expression pattern of genes that were only deleted in patients.
MATERIALS AND METHODS

Case-control cohorts.
All patient and control cohorts included in the analysis are of European origin, have been genetically matched with their respective controls and have been described previously in detail [18] [19] [20] (Table   1 ). The epilepsy subtype classifications were based on the terminology proposed by the Commission on Classification and Terminology of the International League against Epilepsy (ILAE) [1] . For an extended description of phenotypes, sample recruitment, genotyping and CNV calling see the Supplementary Information file. Briefly, the epilepsy cohort was composed by 1,366 GGE cases genotyped with the Genome-Wide Human SNP Array 6.0 platform (Affymetrix, Santa Clara, CA, USA) [18] plus 281 and 807 RE and AFE cases, respectively which were genotyped using the Human OmniExpress BeadChip platform (Illumina Inc., San Diego, CA, U.S.A.). The control set was composed of 5,234 samples extracted from the original GGE study and genotyped with the Genome-Wide Human SNP Array 6.0 platform (n= 5,234 [18] ) plus 1,512 controls extracted from the original RE study [19] and genotyped using the Human OmniExpress BeadChip platform, totaling 6,746 control individuals ( Table 1 ).
Microdeletion calling
The software PennCNV was used as the CNV calling algorithm following author recommendations for the corresponding Affymetrix and Illumina arrays [25] . Microdeletions were defined as autosomal CNVs with deletion behavior spanning at least 400kb in both Affymetrix and Illumina arrays to enrich for likely pathogenic variants. Additionally, to ensure highly reliable calls we only considered microdeletions involving at least 200 probes for the Affymetrix 6.0 platform [ 18 26] .
Considering that amount of probes of the Illumina Omni express arrays (n= ~740,000 markers) was less than half (40%) of the Affymetrix 6.0 platform (~1,850,000 markers), but at the same time less prone to false positives [26] , a threshold of 100 markers was applied to the Illumina calls. Only rare microdeletions, defined by a cohort specific frequency below 1% were considered for further analysis. Microdeletion frequency was calculated considering only the control cohort (n= 6,746). Burden statistics.
For the combined epilepsy dataset, we evaluated patient and control autosomal microdeletion burden using a binomial logistic regression model implemented in the R statistical software [27] . To account for possible bias introduced due to the different genotyping platforms, we adjusted for this factor in the regression by including "platform" as a covariate in the model. Corresponding odds ratios (ORs) and 95%-confidence intervals (C.I.) were estimated from the log-likelihood function, 
Microdeletions subsets interrogated.
We evaluated burden enrichment within 8 microdeletions subsets: 1) All microdeletions; 2) microdeletions overlapping hotspot loci; 3) microdeletions outside hotspot loci; 4) microdeletions overlapping "constrained" genes; 5) microdeletions overlapping "neurodevelopmental" genes; 6) microdeletions overlapping "ASD-related" genes (Autism Spectrum Disorders); 7) microdeletions overlapping "DDG2P" genes; and 8) microdeletions overlapping "loss of function intolerant" genes.
While known CNV hotspot loci were extracted from a previous microdeletion revision [14] (No. genes = 330). Here, for subset number 4) we define "constrained" genes as those not overlapped by a CNV of the CNV control map reported by Zarrei et al, 2015 [8] which constitutes a curated version of the database of genomic variants (DGV) on healthy individuals (No. genes = 20.208). For subset 5), "neurodevelopmental" genes were extracted from the original GGE study [18] and defined based on literature and database queries [18 28] (No. genes = 1.559). For subset 6), "ASD-related" genes were extracted from Uddin et al, 2014 [29] and defined as those enriched for deleterious exonic de novo mutations in comparison with healthy siblings (No. genes = 1.683); For subset 7)
"DDG2P" genes were extracted from a curated list of genes reported to be associated with developmental disorders, compiled by clinicians as part of the DDD study [30] to facilitate clinical feedback of likely causal variants (No. genes = 294; https://decipher.sanger.ac.uk/ddd#ddgenes). Tissue specific expression analysis. [32] adjusting for genes actually present in the InWeb network.
Gene
RESULTS.
The analysis was performed in two stages: First, the combined autosomal burden analysis for the entire epilepsy cohort (GGE+RE+AFE) followed by epilepsy subtype burden analyses (GGE, RE and AFE independently). In both strategies we tested burden enrichment among eight microdeletions microdeletions overlapping "Developmental Disorders" genes (DDG2P); and finally 8)
microdeletions overlapping "loss of function intolerant" genes [31] .
Microdeletion frequency: Combined burden analysis.
To investigate the overall contribution of microdeletions in the etiology of common types of epilepsy, we combined all the published microdeletions found in the GGE cohort [18] with the genome-wide microdeletions identified in RE [19] and AFE [20] For the combined results, the most significant enrichment was observed for microdeletions overlapping one of the 12 hotspot loci (adjusted P = 1.99 x 10 -12 ; OR = 6.99; 95%-CI: 4.2-11.97), which is in agreement with previous observations in the GGE cohort that considered only 7 hotspot loci [18] . In this regard, we decided to examine the contribution of microdeletion burden in epilepsy patients outside these known hotspot loci. Thus, a total of 58 microdeletions were filtered out from the analysis ( Supplementary Table S1 ). The contribution of microdeletions inside these regions is substantial, and the overall enrichment did not reach significance after hotspot loci had been removed (adjusted P = 0.17; OR = 1.34; 95%-CI: 1.03-1.73).
Microdeletion distribution: Epilepsy sub-type burden analysis
We hypothesized that microdeletions outside of the hot spot loci are also conferring risk for the disease but are more heterogeneously distributed across the genome and epilepsy subtype specific.
In this regard, we subsequently compared the microdeletion burden including hotspot loci for each epilepsy sub-type (GGE, AFE, and RE, Supplementary Figure S2 ) and then investigated whether we can identify enrichment for candidate microdeletion subsets not overlapping these regions ( figure   1 ). As expected, the analysis showed that GGE patients were most significantly enriched for microdeletions overlapping hotspot loci (adjusted P = 1.22x10 -12 ; OR = 7.45; 95%-CI: 4.21-13.5) and overlapping neurodevelopmental genes as previously shown in [18] . Interestingly, microdeletions overlapping neurodevelopmental genes not overlapping hotspot loci remained significant (adjusted P = 1.12x10 -2 ; OR = 2.85; 95%-CI: 1.62-4.94). In contrast, RE patients showed nominal significance and a large effect size of microdeletions overlapping hotspot loci but this did not survive multiple testing correction (figure 1; nominal P = 0.029; adjusted P = 0.24; OR = 8.13; 95%-CI: 0.92-97.79).
AFE patients did not show significant differences with control samples within hotspot loci (P = 1; OR = 2.85; 95%-CI: 0.13-25.9). Furthermore, RE and AFE samples were not enriched for any of the microdeletion subsets interrogated outside hotspot loci. Sample count of all the microdeletion subsets evaluated is provided in Supplementary Table S3 .
Microdeletions gene content: Epilepsy candidate gene identification outside hotspot loci.
To extract additional epilepsy genes of interest overlapped by microdeletions outside hotspot loci (already examined in [18] ) we generated a short list of potential epilepsy candidate genes that can be followed up in future studies. First, we performed a gene-oriented burden analysis outside hotspot loci comparing the number of cases carrying a microdeletion within a gene against the corresponding number of controls. We detected nominal association for NRXN1 and RBFOX1 genes ( Table 2 , p nominal = 0.019, No. of cases = 3, No. controls = 0). In this regard, due to the low frequency of microdeletion events, extraordinary large sample sizes are required to identify significant enrichment for a particular gene. Secondly, we report genes outside hotspot loci boundaries, affected more than once by microdeletions in cases and not in controls (e.g case-only genes). Candidate genes fulfilling these filtering criteria are resumed in Table 2 . Finally, we also highlight genes with at least one case affected by a microdeletion belonging to the DDG2P gene list for developmental disorders [30] , namely SKI, KCNA2, GCH1, and DVL1.
Overall, NRXN1, PCDH7, TSNARE1 and RBFOX1, have been reported previously associated with GGE[ 18 22 ]. While microdeletions overlapping RBFOX1 were expected to be present also in the AFE cohort based on the original study [20] , we also identified additional microdeletions overlapping [8] .
Microdeletions gene content: Tissue specific expression and network analysis of candidate genes
To further evaluate the plausible involvement of the selected candidate genes in neuronal processes and epilepsy, we performed a global gene set enrichment analysis using expression data from the GTEx portal (http://www.gtexportal.org/home/; version3). We compared the expression patterns of the 12 genes deleted more than once in patients (Table 2 ) versus the 92 genes deleted more than once in controls. While the analysis shows an emerging pattern for brain tissues not observed in controls, after correction for multiple testing, the observation was not significant ( figure 2) . Finally, to evaluate the entire pool of genes only deleted in patients in a network context we used the Disease Association Protein-Protein Link Evaluator (DAPPLE) [33] to assess if these genes form protein-protein interactions networks that have more interconnections than expected. We ran the analysis for each epilepsy syndrome separately, with only the GGE syndrome being significantly 
DISCUSION
We have previously shown in GGE patients an enriched burden of microdeletions overlapping neurodevelopmental genes in comparison to controls and that the signal was particularly concentrated on seven hotspot loci [18] . In the present work we moved one step further and examined if this burden extends broadly (combined analysis) and/or specifically to other types of epilepsies (sub-type analyses). While we were able to replicate the original GGE signal, novel analyses were introduced to further characterize the GGE burden, as well as in the RE and AFE cohorts, including: the evaluation of twelve hotspot loci, microdeletions overlapping constrained genes, neurodevelopmental disorders genes (DDG2P) and Loss of Function Intolerant (LoF) genes.
Moreover, when focusing on genes exclusively deleted in cases we were able to extract additional genes with plausible pathogenic behavior.
Burden of microdeletions in epilepsy patients
In the combined analysis, we found a 1.39 fold excess of patients with microdeletions compared to controls, which translates in to 4.85% of epilepsy patients carrying at least one microdeletion compared to 3.47% of controls. At this level, microdeletions exhibit a mild impact on the overall genetic susceptibility towards common epilepsy types, which is particularly concentrated on GGE.
The spectrum of 134 microdeletions identified in patients of the combined epilepsy analysis contained a high proportion of recurrent microdeletions at genomic rearrangement hotspot loci (32.34 %), again with the highest fraction coming from GGE patients (90.47 %). Although, we controlled for array differences (Affymetrix vs Illumina) in the combined analysis, we can not be certain that platform bias was completely removed and thus conclude that RE or AFE do not have additional microdeletion enrichment to contribute, especially considering that individuals with microdeletions only account for a minor proportion of patients. Similarly, in the sub-type specific analysis we only compared platform matched cases with controls, nevertheless the complete contribution of microdeletions to the presentation of each epilepsy sub-type could be underestimated since our analysis was restricted only to high confidence calls and large microdeletions based on high-throughput genotyping. Furthermore, our cohort size, in particular the RE cohort, is still too small to identify microdeletions with small disease risk. We also acknowledge the high heterogeneity of the AFE cohort (see definition in Supplementary Information) where the general pool of patients with focal epilepsy could overshadow specific and rare pathogenic events. Larger samples size, prospective studies and deep phenotyping will allow the evaluation of other rare variants in the presence of microdeletions that could explain the specific outcomes commonly observed in neurodevelopmental disorders. Still, considering the aforementioned caveats, our results enable of us to elucidate the followings topics.
The landscape of microdeletions overlapping and not overlapping hotspot loci is epilepsy subtypespecific
In line with the original GGE study [18] , the strongest combined enrichment was found for microdeletions overlapping known microdeletion syndrome hotspot loci. The level of association did not increase with the inclusion of additional 5 hotspot loci to the analysis. These microdeletions are commonly found in patients with other highly comorbid traits such as ASD, ID and SCZ giving rise to a complex network of neurodevelopmental phenotypes [14 16 ]. The specific effect of each of the hotspot loci evaluated has been difficult to determine and certainly the outcome of microdeletions overlapping these regions is not epilepsy exclusive.
When these regions are considered, sub-type analyses show that for the GGE cohort, the strongest signal falls within genes overlapping neurodevelopmental genes (as previously shown in [18] ). In contrast, for RE the frequency of microdeletions was similar to controls in all subsets exanimated, with the exception of a modest enrichment and a large OR observed for microdeletions overlapping ASD-related genes (Supplementary figure S2) . While the latter observations was not significant we can not rule out that future larger studies will identify a microdeletion burden. The AFE sub-type analysis did not show enrichment for any of the investigated microdeletion subsets with hotspots included. In this regard, we observed that the contribution of these regions is compelling and epilepsy subtype-specific. Notably, by removing them from the analysis, the only significant enrichment that remained was for genes associated with neuronal development in the GGE subtype ( Figure 1 ).
The enrichment for GGE with hotspot loci has previously been shown to be more significant in patients with GGE and ID [34] . In this regard, in contrast to severe neurodevelopmental disorders with or without seizures [35] the microdeletion burden for common epilepsy patients with normal social and intellectual skills (i.e. high-functioning) is expected to be modest, thus we cannot rule out that GGE patients in our cohort with hotspot microdeletions represent those at the lower boundaries of the IQ distribution in the general population. It has previously been shown that CNVs at hotspot loci affect cognition in patients and controls [36 37] . Given that the majority of the identified hotspot CNVs have been also associated with intellectual disability, well phenotyped cohorts are needed in future studies to investigate whether seizures are also an independent consequence of these particular microdeletions.
Established disease and candidate genes only deleted in patients outside of microdeletion hotspots
Four patients carried microdeletions overlapping the established developmental disorder genes SKI, KCNA2, GCH1 and DVL1. As an additional support for haploinsufficiency of these genes, all show in >60,000 population controls depletion for loss-of-function variants (http://exac.broadinstitute.org).
We identified nominal enrichment for the gene encoding the adhesion molecule neurexin 1 (NRXN1) and the splicing regulator RNA-binding protein fox-1 homolog (RBFOX1), which were previously implicated in epilepsy and neurodevelopmental disorders[20 22 23 38 39 ]. To identify plausible candidate genes for epilepsy with potentially large effects, we selected genes exclusively overlapped by at least two microdeletions in epilepsy patients. We identified 10 candidate genes at seven loci. These autosomal microdeletions involved several genes previously implicated in epilepsy and neurodevelopmental disorders. Specifically, the genes encoding T-SNARE Domain Containing 1 (TSNARE1) and protocadherin 7 (PCDH7) have been highlighted previously in our GGE microdeletion analysis [18] (1,366 patients and 5,234 controls) which was entirely integrated in the present study.
Furthermore, with the analysis of other types of epilepsies we detected one RE patient with a partial NRXN1 microdeletion and one AFE patient with a complete PCDH7 deletion. These observations suggest their role as broader epilepsy risk factors rather than syndrome specific variants of high effect. Furthermore, our gene-centric (compared to microdeletion-centric) analysis could narrow down four large microdeletions to PCDH7, PACRG, LOC102723362 and LOC101928137 as the only remaining genes not deleted in controls respectively. We acknowledge the limitations of this analysis since we do not have the power to assign a meaningful p-value to these detected genes.
Expression and network analysis.
In the expression analysis of candidate genes we did not observe significant brain tissue enrichment, probably because the number of included genes was small and not all of them may be involved in epilepsy. While global or individual-gene brain expression patterns would have been informative, the results are not conclusive and thus we cannot rule out candidates based on gene expression filtering. The network analysis resulted in significant interconnection only for the GGE syndrome. The likely reason for this is the difference in the number of regions between the syndromes rather than a difference in the underlying biology. These results are encouraging, considering that we use non cell-type specific networks and did not filter the network based on tissue-specific gene expression. The enriched KEGG Long Term Depression (hsa04730) and Long Term Potentiation (hsa04720) networks represent plausible neuronal enriched networks in epilepsy patients.
In summary, we show that the microdeletion enrichment in epilepsy patients is focused towards genes involved in neurodevelopmental processes. Patients with GGE syndrome exhibit the highest microdeletion frequency, especially at hotspot loci. Apart from these loci ultra-rare heterogeneous deletions contribute significantly to GGE whereas microdeletion frequency and distribution in AFE is indistinguishable from controls. The RE cohort is the smallest and therefore has the lowest statistical power for association discovery. However, the RE cohort shows nominal enrichment for hotspot loci microdeletions. There was some support for ultra-rare microdeletions as plausible epilepsy candidate genes. Our study demonstrates, that the contribution of microdeletions in common epilepsies is subtype specific. With increasing cohort sizes, the genetic architecture of the epilepsies and the contribution of microdeletions will become more evident. Despite these differences, candidate genes can be found commonly deleted in more than one epilepsy type. Thus, the present findings contribute to our understanding of the structural genetic architecture of epilepsies from an overall and sub-type specific perspective. Figure 2 . Tissue specific gene expression of epilepsy patient deleted genes. Tissue enrichment analysis using publicly available expression data from pilot phase of the Genotype-Tissue Expression project (GTEx), version 3 (see Methods). Overall, 45 individual tissues were assayed and grouped in to nine categories by color (upperright box). Left panel: Results for genes identified to be deleted more than once in patients and not in controls (n = 12). Right panel: Results for genes deleted more than once in controls and not in patients (n = 96). For both analysis the significance threshold is denoted by vertical red line (P=1.90 x 10 -3 ).
Figure 3. Protein-protein interaction network of GGE exclusively deleted genes.
Total interacting structures found in GGE exclusively deleted genes (not deleted in controls) are shown. Each gene (node) in the network is colored based on the significance of having more-than-expected edges (interactions) following the p-value legend provided at the upper-right corner. Significant cluster is enclosed within a circle.
